ATOSSA THERAPEUTICS, INC. (ATOS) Stock Profile — Insider Trades & Financials

Net Income-$10.9M

EPS$-0.18

Market Cap$41.5M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Steven Quay

CEO & Executive Director

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The companyâs lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Founded: 2009
Employees: 15
Headquarters: Seattle, Washington, United States

⚡

Core Efficiency

ROE?

-27.79%

ROA?

-22.97%

D/E Ratio?

0.21

📊

Profitability Ratios

Current Ratio?

5.53

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 16, 2026 (in 129 days)

Annual Report (10-K) — Based on filing pattern

Aug 16, 2026

Predicted10-K

Mar 25, 2026

10-KQ4 20258d after period end

Nov 12, 2025

10-QQ3 202511d after period end

Aug 12, 2025

10-QQ2 202511d after period end

May 13, 2025

10-QQ1 202512d after period end

Mar 25, 2025

10-KQ4 20248d after period end

Nov 12, 2024

10-QQ3 20244d after period end

Aug 12, 2024

10-QQ2 202411d after period end

May 13, 2024

10-QQ1 202412d after period end

Loading company sections...

ATOSSA THERAPEUTICS, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness